LIOTHYRONINE SODIUM
Generic: LIOTHYRONINE SODIUM
Teva Pharmaceuticals USAManufacturer
ORALRoute
LIOTHYRONINE SODIUMActive Substance
2018-10-26Original Approval
LIOTHYRONINE SODIUM is FDA application ANDA211510, sponsored by TEVA PHARMS USA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2023-12-04
Liothyronine Sodium Tablets, USP 5 mcg, 100-count bottle, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. CFailed Impurities/Degradation Specifications
Class II2014-04-22
Liothyronine Sodium Tablets, USP 5 mcg, Rx Only, a) 100-count bottle NDC 42794-018-02 and b) 1000-count bottle NDC 42794Cross Contamination with Other Products: Four lots of Liothyronine Sodium Tablets, USP 5 mcg are bei
Class II2023-10-20
Liothyronine Sodium Tablets, USP, 5 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc.Failed Impurities/Degradation Specifications.
Class II2023-10-20
Liothyronine Sodium Tablets, USP, 25 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, IncFailed Impurities/Degradation Specifications.
Top Reported Reactions
1
HEADACHE
498 reports
2
DRUG INEFFECTIVE
451 reports
3
HYPERTENSION
354 reports
4
DYSPNOEA
326 reports
5
HYPOTHYROIDISM
318 reports
6
ASTHMA
308 reports
7
FATIGUE
297 reports
8
THERAPEUTIC PRODUCT EFFECT INCOMPLETE
296 reports
9
GASTROOESOPHAGEAL REFLUX DISEASE
293 reports
10
BURNING SENSATION
286 reports